EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses

Yi Luan, Desheng Xian, Changwen Zhao, Xin Qing, Hanlin He, Kaixuan Zheng, Wenjun Song, Taijiao Jiang, Wenjian Wang, Chaohui Duan

Frontiers in Pharmacology · 28.10.2024 · 15

DOI: 10.3389/fphar.2024.1441233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.10.2024. Verfasst von Yi Luan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangz…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer, categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant global health challenge. The development of drug resistance and the heterogeneity of the disease necessitate the identification of novel therapeutic targets to improve patient outcomes.

Methods

We conducted a genome-wide Mendelian randomization (MR) and colocalization analysis using a comprehensive dataset of 4,302 druggable genes and cis-expressed quantitative trait loci (cis-eQTLs) from 31,884 blood samples. The study integrated genomic analysis with eQTL data to identify key genes associated with lung cancer risk.

Results

The analysis revealed five actionable therapeutic targets for NSCLC, including LTB4R, LTBP4, MPI, PSMA4, and TCN2. Notably, PSMA4 demonstrated a strong association with both NSCLC and SCLC risks, with odds ratios of 3.168 and 3.183, respectively. Colocalization analysis indicated a shared genetic etiology between these gene expressions and lung cancer risk.

Conclusion

Our findings contribute to precision medicine by identifying druggable targets that may be exploited for subtype-specific lung cancer therapies.

Schlagwörter

Stichwörter der Autor:innen

GWASMendelian randomizationcolocalization analysesdrug targetlung cancer

Autor:innen und Institutionen

  • Laboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • State Key Laboratory of Chemical Resource Engineering and Beijing Laboratory of Biomedical Materials, Key Laboratory of Biomedical Materials of Natural Macromolecules, Ministry of Education, University of Chemical Techn…
  • Westchina Hospital, Sichuan University, Chengdu, China.
  • Guangzhou Medical University, Guangzhou, Guangdong, China.
  • School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China.

Zitieren

APA

Luan, Y., Xian, D., Zhao, C., Qing, X., He, H., Zheng, K., Song, W., Jiang, T., Wang, W., & Duan, C. (2024). Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1441233

Vancouver

Luan Y, Xian D, Zhao C, Qing X, He H, Zheng K, et al. Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1441233

BibTeX
@article{Luan2024,
  author = {Luan, Yi and Xian, Desheng and Zhao, Changwen and Qing, Xin and He, Hanlin and Zheng, Kaixuan and Song, Wenjun and Jiang, Taijiao and Wang, Wenjian and Duan, Chaohui},
  title = {Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1441233}
}
Kostenlos starten →